Clinical Trial for Integrated Care to Help At Risk Teens (iCHART) Intervention

October 29, 2026 updated by: Stephanie Stepp, University of Pittsburgh

The Center for Enhancing Triage and Utilization for Depression and Emergent Suicidality (ETUDES) in Pediatric Primary Care-iCHART RCT

This protocol will test the effectiveness of an intervention, iCHART (integrated Care to Help At-Risk Teens) and facilitate recruitment for other studies in the larger ETUDES Center grant, which are focused on treatment development for target risk factors for suicidal behavior, specifically, sleep, anhedonia, and stress related to cyber-victimization. This study will recruit 900 adolescents which will be enrolled in a randomized controlled trial to test iCHART and will be randomized to iCHART or treatment as usual (TAU). Based on previous work, the investigators hypothesize that iCHART, compared to TAU, will decrease suicide-related events by 50%. The investigators will use implementation science methods to assess contextual factors (i.e., barriers and facilitators) and implementation outcomes specifically, acceptability, feasibility, appropriateness, and cost for our predictive algorithm and iCHART to inform future implementation efforts and promote health equity.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

iCHART is an intervention that includes 3 components previously studied in within the ETUDES Center including the:

  1. Safety planning app for suicidal youth which enables a primary care provider to streamline the gold standard of care for those with current suicidality symptoms through an app (instead of a paper based version);
  2. Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement;
  3. Text Messages which aims to provide texts for 2-3 weeks to motivate youth to engage with the safety plan.

Aim 1. Test the effectiveness of iCHART in reducing suicide-related events at 6 months, the primary outcome, and examine mediators and moderators of treatment response. The investigators hypothesize: 1) iCHART will reduce suicide-related events; 2) Individual-, family-, and neighborhood-level risk and protective factors will moderate response; and 3) Examine a predictive algorithm to examine heterogeneity of treatment response.

Aim 2. Examine barriers, facilitators, and implementation outcomes specifically, acceptability, feasibility, appropriateness, and cost for iCHART to inform future implementation efforts and promote health equity. Barriers and facilitators that span multiple levels of context (e.g., aspects of clinic workflows, provider beliefs and knowledge) are expected to be uncovered. Further, incorporating iCHART in pediatric primary care will be viewed as feasible, acceptable, and appropriate by youth and caregivers across different racial and ethnic groups.

Study Type

Interventional

Enrollment (Actual)

765

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Gibbsboro, New Jersey, United States, 08026
        • Gibbsboro
    • Pennsylvania
      • Johnstown, Pennsylvania, United States, 15905
        • Conemaugh Memorial Medical Center-Family Medicine
      • Philadelphia, Pennsylvania, United States, 19104
        • CHOP Primary Care, CHOP Campus
      • Philadelphia, Pennsylvania, United States, 19128
        • Roxborough
      • Philadelphia, Pennsylvania, United States, 19139
        • CHOP Primary Care, Cobbs Creek
      • Philadelphia, Pennsylvania, United States, 19139
        • Karabots
      • Pittsburgh, Pennsylvania, United States, 15213
        • UPMC Center for Adolescent and Young Adult Health
      • Pittsburgh, Pennsylvania, United States, 15213
        • Children's Community Pediatrics (CCP) of Children's Hospital of Pittsburgh UPMC
      • Pittsburgh, Pennsylvania, United States, 15213
        • UPMC Family Medicine
      • Pittsburgh, Pennsylvania, United States, 15217
        • Kids Plus Pediatrics (KPP)
      • Reading, Pennsylvania, United States, 19604
        • Berks Community Health Center
      • Springfield, Pennsylvania, United States, 19064
        • Springfield
      • West Chester, Pennsylvania, United States, 19380
        • CHOP Primary Care, West Chester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • YOUTH

    • Youth will be age 12-18 and speak English.
    • Youth will have current depression or suicidal behavior. Suicidal behavior for iCHART (N=900) is defined as past suicidal thoughts in the past two weeks as indicated by clinician interview or report or as indicated by responses to a standardized assessments such as the PHQ-9, PHQ-9M, ASQ, CSSRS, or Behavioral Health Screen, or seeking acute care or clinical contact for mental health crisis/problem in the past year.
  • CAREGIVERS/PARENTS

    • Parents/caregivers of youth in the study must be at least 18 years old and their child must be willing to participate in the study. Caregivers/parents must be able to speak English. Parents are considered biological/adoptive parents or have court documentation that they can provide consent for research as a legal guardian of a youth. Only 1 parent/caregiver will be engaged in research, but in case 1 parent is unavailable, the other may be engaged (meaning it doesn't have to be the same parent participating in assessments/interviews throughout youth study participation).

Exclusion Criteria:

  • YOUTH

    • Exclusion criteria include conditions that might impair their ability to effectively deploy ETUDES interventions, including:
    • current manic or psychotic episode, presence of a life-threatening medical condition requiring immediate treatment, intellectual or developmental disability precluding comprehension of study procedure. The latter will be assessed by parental report of placement in self-contained Special Education classes, EHR review, and during the consent/assent and/or baseline to determine if the participant is not understanding research procedures.
    • Participants without access to a phone and/or tablet to interact with components of the intervention that require a phone will be excluded.
  • CAREGIVERS/PARENTS

    • There are no specific exclusion criteria for caregivers and providers. However, as mentioned in the inclusion criteria, caregivers will be excluded if they are not the biological parent or court-appointed guardian of the youth being interviewed.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: iCHART

iCHART is an intervention that includes 3 components previously studied in within the ETUDES Center including a:

  1. Safety Planning App for suicidal youth which enables a clinician to streamline the gold standard of care for those with current suicidality symptoms through an app (instead of a paper based version);
  2. Mental Health Screener questionnaire that gathers additional mental health symptoms, treatment preferences, and family's readiness for treatment engagement to help clinicians make a personalized, tailored treatment plan a suicidal youth is more likely to adhere to;
  3. Text Messages which aims to provide texts for 2-3 weeks to motivate you to engage with the safety plan and recommended treatment following the patient visit.

Participants will receive psychoeducation and referral to a mental health treatment provider, if needed.

The Safety Planning App will guide clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.

The Mental Health Screener is a decision support tool to guide clinicians to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.

The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.

Participants will receive psychoeducation and referral to a mental health treatment provider, if needed.

Active Comparator: Treatment As Usual (TAU)

Participants in this group will receive usual care from their clinician which may will include development of a paper safety plan.

Participants in this group will receive usual care from their clinician which may include development of a paper safety plan.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suicide related event
Time Frame: Cumulative through 6-month follow up

Suicidal Event definition: combination of items on CSSRS + CASA: actual attempt=yes; interrupted attempt=yes; aborted attempt=yes; preparatory acts=yes; emergency referral=yes in CSSRS and include emergency referral items in CASA that are suicide related (receipt of treatment from a medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center). Note this is a composite score.

Cumulative through 6-month follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Suicide related event
Time Frame: Cumulative through 12-month follow up

Suicidal Event definition: combination of items on CSSRS + CASA: actual attempt=yes; interrupted attempt=yes; aborted attempt=yes; preparatory acts=yes; emergency referral=yes in CSSRS and include emergency referral items in CASA that are suicide related (receipt of treatment from a medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center). Note this is a composite score.

Cumulative through 12-month follow up
Depression Severity
Time Frame: Cumulative 6-month follow up

Total scores from the Patient Health Questionnaire (PHQ-9-M) will be used to assess depression severity.

Cumulative 6-month follow up
Time from randomization to first suicide related event
Time Frame: Cumulative through 6-month follow up

Time of onset to suicide related to event. Dates are collected on CSSRS and CASA when suicidal behavior events occur (CSSRS) and referrals are made to medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center.

Cumulative through 6-month follow up
Time from randomization to first suicide related event
Time Frame: Cumulative through 12-month follow up

Time of onset to suicide related to event. Dates are collected on CSSRS and CASA when suicidal behavior events occur (CSSRS) and referrals are made to medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center.

Cumulative through 12-month follow up
Frequency of suicide-related events
Time Frame: Cumulative through 6-month follow up

Number of suicide related events across sample collected from CSSRS and CASA.

Cumulative through 6-month follow up
Frequency of suicide-related events
Time Frame: Cumulative through 12-month follow up

Number of suicide related events across sample collected from CSSRS and CASA.

Cumulative through 12-month follow up
Aborted Attempts
Time Frame: Cumulative through 6-month follow up

Behavior section, aborted (self-interrupted) attempt endorsed for interval covered on CSSRS.

Cumulative through 6-month follow up
Aborted Attempts
Time Frame: Cumulative through 12-month follow up

Behavior section, aborted (self-interrupted) attempt endorsed for interval covered on CSSRS.

Cumulative through 12-month follow up
Interrupted Attempts
Time Frame: Cumulative through 6-month follow up

Behavior section, interrupted attempt endorsed for interval covered on CSSRS.

Cumulative through 6-month follow up
Interrupted Attempts
Time Frame: Cumulative through 12-month follow up

Behavior section, interrupted attempt endorsed for interval covered on CSSRS.

Cumulative through 12-month follow up
Actual attempt (non-fatal)
Time Frame: Cumulative through 6-month follow up

Behavior section, actual attempt endorsed for the interval covered on CSSRS.

Cumulative through 6-month follow up
Actual attempt (non-fatal)
Time Frame: Cumulative through 12-month follow up

Behavior section, actual attempt endorsed for the interval covered on CSSRS.

Cumulative through 12-month follow up
Preparatory acts taken for a suicide attempt
Time Frame: Cumulative through 6-month follow up

Suicidal behavior indicator endorsed for preparatory acts or behavior toward imminent suicidal behavior endorsed for the interval covered on CSSRS.

Cumulative through 6-month follow up
Preparatory acts taken for a suicide attempt
Time Frame: Cumulative through 12-month follow up

Suicidal behavior indicator endorsed for preparatory acts or behavior toward imminent suicidal behavior endorsed for the interval covered on CSSRS.

Cumulative through 12-month follow up
Emergency referral for increased suicidal ideation
Time Frame: Cumulative through 6-month follow up

Study emergency referral recorded in connection with increased suicidal ideation.

Cumulative through 6-month follow up
Emergency referral for increased suicidal ideation
Time Frame: Cumulative through 12-month follow up

Study emergency referral recorded in connection with increased suicidal ideation.

Cumulative through 12-month follow up
Emergency referral for increased suicidal ideation
Time Frame: Cumulative through 6-month follow up

Designated CASA emergency referral items where the referral is suicide related (on items related to receipt of treatment from a medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center).

Cumulative through 6-month follow up
Emergency referral for increased suicidal ideation
Time Frame: Cumulative through 12-month follow up

Designated CASA emergency referral items where the referral is suicide related (on items related to receipt of treatment from a medical or psychiatric inpatient facility, emergency department, outpatient facility, or crisis center).

Cumulative through 12-month follow up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Service utilization
Time Frame: Baseline

Frequency and type of concurrent psychiatric services will be measured through the Child and Adolescent Services Assessment (CASA).The CASA is a semi-structured face-to-face interview. The interview mixes close-ended questions that are often answered by "yes" or "no" with open-ended questions that allow elaboration. The CASA is comprised of four sections: The Child Health Services Screen, The Detailed Child Services Form, Attitudes Toward Services for Children and Adolescents, and Family Demographic and Financial Information (in the parent version only).

Baseline
Service utilization
Time Frame: 6-month follow up

Frequency and type of concurrent psychiatric services will be measured through the Child and Adolescent Services Assessment (CASA).The CASA is a semi-structured face-to-face interview. The interview mixes close-ended questions that are often answered by "yes" or "no" with open-ended questions that allow elaboration. The CASA is comprised of four sections: The Child Health Services Screen, The Detailed Child Services Form, Attitudes Toward Services for Children and Adolescents, and Family Demographic and Financial Information (in the parent version only).

6-month follow up
Service utilization
Time Frame: 12-month follow up

Frequency and type of concurrent psychiatric services will be measured through the Child and Adolescent Services Assessment (CASA).The CASA is a semi-structured face-to-face interview. The interview mixes close-ended questions that are often answered by "yes" or "no" with open-ended questions that allow elaboration. The CASA is comprised of four sections: The Child Health Services Screen, The Detailed Child Services Form, Attitudes Toward Services for Children and Adolescents, and Family Demographic and Financial Information (in the parent version only).

12-month follow up
Safety planning and BRITE app use
Time Frame: Post-intervention-through 3 months (adolescents & caregivers)

Use of the technical components of interventions and web portals of iCHART including: the number and proportion of adolescents, parents, and providers who have engaged with the application components over time and reported pre- and post- updates to the intervention app and web portals:

  • Completed daily mood rating (yes/no)
  • Number of mood ratings
  • Personalized the app by adding/updating Content (yes/no)
  • Completed activities on the app (yes/no)
  • Number of completed activities
  • Number of logins
Post-intervention-through 3 months (adolescents & caregivers)
Intervention Acceptability
Time Frame: Post-intervention-1 month follow up (adolescents, caregivers)

Acceptability of the iCHART intervention will be assessed through the 4 item Acceptability of Intervention Measure (AIM). Scales can be created for by averaging responses. Scale values range from 1 to 5. Higher scores indicate greater acceptability. The items include questions to determine if intervention is appealing to, liked by, welcomed by, and approved by study population.

Post-intervention-1 month follow up (adolescents, caregivers)
Intervention Usability
Time Frame: Post-intervention-1 month follow up (adolescents, caregivers)

Usability of the iCHART intervention will be assessed through the Post System Satisfaction Usability Questionnaire (PSSUQ). PSSUQ follows a 7-point Likert Scale (+ NA option). The overall result is calculated by averaging the scores from the 7 points of the scale. It also has 3 sub-scales, namely system usefulness, information quality, and interface quality. The sub-scales provide a more detailed breakdown of different factors affecting the intervention. PSSUQ score starts with 1 (strongly agree) and ends with 7 (strongly disagree). The lower the score, the better the performance and satisfaction.

Post-intervention-1 month follow up (adolescents, caregivers)
Intervention Feasibility
Time Frame: Post-intervention-1 month follow up (adolescents, caregivers)

Feasibility of the iCHART intervention will be assessed through the 4 item Feasibility of Intervention Measure (FIM). Scales can be created for by averaging responses. Scale values range from 1 to 5. Higher scores indicate greater feasibility. The items include questions to determine if intervention is easy to use and seems possible or doable to implement in study population.

Post-intervention-1 month follow up (adolescents, caregivers)
Intervention Appropriateness
Time Frame: Post-intervention-1 month follow up (adolescents, caregivers)

Intervention appropriateness of the iCHART intervention will be assessed through 4 item Intervention Appropriateness Measure (IAM). Scales can be created for by averaging responses. Scale values range from 1 to 5. Higher scores indicate greater appropriateness. The items include questions to determine if intervention is a good match, fitting, suitable, or seems applicable to the study population.

Post-intervention-1 month follow up (adolescents, caregivers)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Stephanie Stepp, PhD, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 26, 2023

Primary Completion (Estimated)

April 30, 2027

Study Completion (Estimated)

April 30, 2027

Study Registration Dates

First Submitted

February 8, 2023

First Submitted That Met QC Criteria

February 17, 2023

First Posted (Actual)

March 1, 2023

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 29, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY22020069
  • P50MH115838 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All requests for study data will follow NIMH's data sharing and data use policies. The final completely de-identified dataset(s) will include demographic and clinical data at baseline, and primary and secondary outcomes for all studies, including those funded by the innovation contests. These analytic datasets may also include derived variables with documentation. Our form datasets will include original case report forms, a detailed codebook of variable names, value labels, and programming formats and all study documentation including the protocol and manual of procedures. For descriptive/raw data, study investigators/study staff will upload to NIMH's National Database for Clinical Trials Related to Mental Health Illness (NDCT) on a semi-annual basis all analyzed data being uploaded prior to primary paper publication.

IPD Sharing Time Frame

Beginning 3 months and ending 5 years following "main outcomes" article publications.

IPD Sharing Access Criteria

In addition to public access to the NDCT, proposals should be directed to georgeba2@upmc.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.